Dr. Dai brings a wealth of expertise in navigating global regulations and advancing drug development, with a specialized focus on gene therapy, rare diseases, oncology, and hematology.

In her roles as Executive Director of Regulatory Affairs at Adverum and Director of Regulatory Affairs & CMC at AbbVie (formerly ImmunoGen), she played a pivotal role in crafting regulatory and CMC strategies for cutting-edge treatments like gene therapy and antibody drug conjugates. Notably, at Amicus, Dr. Dai led initiatives that paved the way for crucial therapies, including regulatory approval for an enzyme replacement therapy for Pompe disease, while also exploring innovative approaches to regulatory challenges in gene therapy programs.

Throughout her career at Pfizer, AbbVie, and Enzon Pharmaceuticals, Dr. Dai held positions of increasing responsibility, contributing significantly to research and development efforts and navigating the complex landscape of drug development of biologics, gene silencing and regenerative medicines across various stages of the clinical and commercial lifecycle.

Her academic credentials include a Ph.D. in Biophysical Chemistry from Rutgers University at New Brunswick and a B.S. in Chemistry from Peking University, complemented by post-doctoral training in Structural Biology at the University of Pennsylvania.